FDA — authorised 25 January 2013
- Application: NDA203414
- Marketing authorisation holder: TAKEDA PHARMS USA
- Indication: Labeling
- Status: approved
🇺🇸 Alogliptin and metformin in United States
FDA authorised Alogliptin and metformin on 25 January 2013
Marketing authorisations
FDA
- Application: ANDA210002
- Marketing authorisation holder: INDOCO REMEDIES
- Local brand name: ALOGLIPTIN
- Indication: TABLET — ORAL
- Status: approved
Alogliptin and metformin in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Alogliptin and metformin approved in United States?
Yes. FDA authorised it on 25 January 2013; FDA has authorised it.
Who is the marketing authorisation holder for Alogliptin and metformin in United States?
TAKEDA PHARMS USA holds the US marketing authorisation.